Business Development
Available Technologies
AllerGen encourages investigators to seek patent protection on innovations discovered in their research laboratories. Early-stage break-through technologies that have commercial potential include:
- New diagnostic tests for allergy and asthma (Allergy/asthma gene chips);
- Bio-analytic tests for airborne pollutants and allergens;
- New food products; and
- Clinical trial methodologies that fast-track new allergy and asthma drug candidates.
One of AllerGen's top priorities is to create new linkages among academic institutions, hospitals, government and industry for knowledge and technology transfer. Over the past two years, AllerGen has partnered with 115 organizations that span five global foci (Canada, USA, Australia, UK and Europe).